SGMT

Sagimet Biosciences Inc.

• NASDAQ·36m ago

  Tuesday's ETF Movers: XBI, CRAK

• Benzinga·10/09 11:15

  Sagimet Biosciences To Present 52-Week Results From Its Phase 3 ASC40-304 Open-Label Extension Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris At The 2026 Fall Clinical Dermatology Conference, October 8-11

• NASDAQ·10/05 19:27

  Notable Monday Option Activity: ONT, NET, SGMT

• TipRanks·10/05 10:50

  Analysts Are Bullish on Top Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Sagimet Biosciences, Inc. Class A (SGMT)

• Dow Jones·10/05 10:25

  Sagimet Biosciences Price Target Maintained With a $29.00/Share by HC Wainwright & Co.

• Benzinga·10/05 10:15

  HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

• NASDAQ·10/04 01:02

  Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch

• Dow Jones·10/02 13:16

  Sagimet Biosciences Is Maintained at Buy by Guggenheim

• Benzinga·10/02 13:06

  Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26

• TipRanks·10/02 10:50

  Sagimet Biosciences price target raised to $26 from $25 at Guggenheim

• Seeking Alpha·10/01 21:41

  Sagimet closes down after acne drug denifanstat data, closing of stock offering

• TipRanks·10/01 15:50

  Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Sagimet Biosciences, Inc. Class A (SGMT) and Jade Biosciences (JBIO)

• TipRanks·10/01 13:50

  Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

• Dow Jones·10/01 13:01

  Sagimet Biosciences Is Maintained at Outperform by Oppenheimer

• Benzinga·10/01 12:51

  Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38